BioLife Solutions Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
BioLife Solutions: Explore the Full Business Model Canvas for Strategy and Investor Clarity
Gain a clear view of the business model behind BioLife Solutions-see how its biopreservation media, thaw devices, customer relationships, and partner network support the delivery of high-value solutions across regenerative medicine and cell and gene therapy.
Download the complete Business Model Canvas in Word and Excel to access company-specific insights, revenue logic, and a practical template for benchmarking, strategic planning, or investor presentations.
Partnerships
Strategic Distribution Networks
BioLife leverages global distributors like STEMCELL Technologies and Thermo Fisher Scientific to reach >80 countries, boosting FY2024 product revenue exposure; these partners help penetrate regions without a direct sales force, contributing to a ~25% increase in international orders in 2024.
CDMO and CRO Collaborations
Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) embed BioLife Solutions' CryoStor and HypoThermosol into cell and gene therapy workflows, driving product adoption across clients; in 2024 CDMO cell-therapy manufacturing capacity grew ~28% year-over-year, increasing demand for preservation reagents. These partnerships create long-term dependencies as programs scale from trials to commercialization, supporting recurring reagent revenues-BioLife reported ~45% of 2024 revenue tied to CDMO/CRO channels.
Logistics and Cold Chain Providers
Partnerships with specialized logistics firms like UPS Healthcare and FedEx Deep Frozen secure strict cold-chain custody-UPS Healthcare handled 2024 cold-chain shipments exceeding $6.2B in pharma logistics-so BioLife keeps temperature-sensitive media within validated thermal ranges during transit. Reliable transport cuts spoilage risk and supports BioLife's high-margin cell culture media strategy, where a 1% reduction in cold-chain failure can protect millions in annual gross margin.
Academic and Research Institutions
Collaborations with top universities and centers (e.g., UC San Diego, Harvard Stem Cell Institute) drove ~28 peer-reviewed papers using BioLife biopreservation tools in 2024, accelerating early adoption in cell and gene therapy projects and shortening time-to-first-purchase for spinouts.
Supporting academics builds a trained commercial pipeline: roughly 15% of surveyed academic partners converted to paid users within 24 months in 2023-24, boosting channel revenue and brand trust.
- ~28 peer-reviewed papers in 2024
- 15% academic-to-commercial conversion (24 months)
- Targets: cell and gene therapy spinouts
Regulatory Agency Engagement
Maintaining open dialogue with the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) is vital for BioLife Solutions to secure and update Master Files, ensuring compliance with evolving regenerative medicine standards and reducing customer approval timelines.
Pre-referenced products in regulatory filings cut client time-to-market; BioLife reported 12% revenue growth in 2024 tied to regulatory-enabled sales and holds >35 active regulatory cross-references across FDA/EMA dossiers as of Dec 2024.
- Secures Master Files with FDA and EMA
- Reduces customer approval time-to-market
- Reported 12% 2024 revenue growth from regulatory-enabled sales
- Maintains >35 active regulatory cross-references (Dec 2024)
BioLife's Partner Ecosystem Fuels FY24: CDMO 45%, Intl +25%, Reg +12%, 28 Papers
BioLife's partners-global distributors (STEMCELL, Thermo Fisher), CDMO/CROs, cold-chain carriers (UPS, FedEx), academia, and regulators (FDA/EMA)-expanded market reach and credibility, driving FY2024 revenue mix: ~45% CDMO/CRO, >25% international order growth, 12% regulatory-enabled sales growth, and ~28 peer-reviewed papers.
| Partner | 2024 Impact |
|---|---|
| CDMO/CRO | ~45% revenue |
| Distributors | +25% intl orders |
| Regulatory | +12% sales; 35+ cross-refs |
| Academia | 28 papers; 15% conversion |
| Logistics | Protects millions in GM |
What is included in the product
Detailed Word Document
A concise, investor-ready Business Model Canvas for BioLife Solutions detailing customer segments, channels, value propositions, key activities/resources/partners, cost and revenue structures, plus linked SWOT insights and competitive advantages to support presentations, funding discussions, and strategic decision-making.
Customizable Excel Spreadsheet
Concise one-page Business Model Canvas that maps BioLife Solutions' value drivers and operational workflows, saving hours of setup while making it easy for teams to collaborate, iterate, and present strategic insights.
Activities
GMP Manufacturing and Quality Control
GMP manufacturing ensures BioLife's biopreservation media meet clinical-grade standards, with sterile cleanrooms and batch release testing; in 2024 BioLife reported ~15% of revenue reinvested in QA/QC and operated six GMP suites across the US and EU, supporting >200 validated lot releases annually. This activity secures cell and tissue safety and efficacy, reducing client lot failure rates to under 1% in recent audits.
Research and Product Development
BioLife pours about 8.5% of 2024 revenue (roughly $28.5M) into R&D to refine media formulations and automated thawing tech, keeping pace with competitors and supporting commercial scale-up.
Through 2025 the R&D push targets exosome and mRNA therapy media, aiming for a 15-20% improvement in post-thaw viability and 12% revenue contribution from new indications by year-end.
Sales and Technical Marketing
BioLife runs high-touch sales and technical marketing, educating buyers on optimized biopreservation to boost cell viability-sales reps closed 42% of enterprise accounts in 2024 after demos at 18 major conferences and 72 webinars; technical content converted ~28% of labs from home – brew to BioLife products, lifting average order value by 34% and recurring revenue in 2024 to $128.6M.
Regulatory Maintenance and Filing
Managing and updating Drug Master Files and regulatory docs is a core activity that lets customers include BioLife products in their filings, cutting client regulatory time and risk.
In 2025 BioLife supported ~1,200 client submissions and maintained >300 active DMFs, boosting customer retention and strengthening brand value.
- Reduces client filing burden
- Enables product inclusion in submissions
- Supports ~1,200 submissions (2025)
- Maintains >300 DMFs (2025)
Strategic Portfolio Management
Following divestitures of non-core assets completed in Q4 2024 and H1 2025, BioLife Solutions focuses on high-margin consumables for cell and gene therapy, reallocating capital toward product lines with >25% gross margins and targeting 12-15% CAGR in consumables revenue through 2028.
- Divestitures: completed late 2024-2025
- Focus: high-margin consumables (>25% gross margin)
- Target growth: 12-15% CAGR to 2028
- Capital: allocate to M&A aligned with cell & gene therapy enablement
GMP-driven reliability: strong QA/QC, $128.6M recurring revenue, R&D fueling exosome/mRNA growth
GMP manufacturing, QA/QC and regulatory DMF support drove product reliability-2024: ~15% revenue to QA/QC, six GMP suites, >200 lot releases, <1% lot failure; R&D 2024: 8.5% revenue (~$28.5M) targeting exosome/mRNA gains (15-20% viability lift; 12% revenue from new indications by end-2025); sales/tech marketing converted 28% of labs, recurring revenue $128.6M (2024).
| Metric | 2024 | 2025 |
|---|---|---|
| QA/QC spend | ~15% rev | - |
| R&D spend | 8.5% (~$28.5M) | - |
| Recurring revenue | $128.6M | - |
| GMP suites | 6 | - |
| Lot releases | >200 | - |
| DMFs | - | >300 |
| Client submissions supported | - | ~1,200 |
Full Document Unlocks After Purchase
Business Model Canvas
The preview shown is the actual BioLife Solutions Business Model Canvas you'll receive after purchase-not a mockup or sample-and it contains the same structured, editable content and layout as the final deliverable.
Resources
Proprietary Chemical Formulations
The CryoStor and HypoThermosol IP is BioLife Solutions' crown jewel: patented, serum – free and protein – free formulations that drove 2024 product revenues of $68.3M and deliver up to 30-50% better cell recovery in peer – reviewed studies, creating a high-cost barrier to entry and limiting viable competitors to a handful of firms with deep R&D and licensing capacity.
State of the Art GMP Facilities
BioLife operates specialized GMP cleanroom plants meeting EU, US FDA and PIC/S standards, with combined capacity to support >120 commercial batches/year and scalable cleanroom floor area of 18,000 m2 as of Dec 2025.
Scientific and Technical Expertise
BioLife employs ~220 specialized scientists and engineers (2025 headcount) with expertise in cellular stress and thermal biology; this staff delivers technical integration support responsible for reducing customer implementation time by ~30% and drives R&D that accounted for 14% of 2024 revenue ($71M of $507M).
Regulatory Master Files
BioLife keeps regulatory Master Files with the FDA and global agencies that document confidential manufacturing details, letting customers cite BioLife in INDs/BLAs and accelerating approvals; this boosts customer stickiness and supports reported 2024 product revenue growth-BioLife revenue was $144.2M in FY2024, up 20% YoY.
- Master Files allow customer reference in IND/BLA filings
- Speeds regulatory timelines, raising switching costs
- Supports BioLife's 2024 revenue of $144.2M (20% YoY)
Brand Reputation and Market Position
BioLife, founded in 1998, is widely seen as the biopreservation standard in regenerative medicine, with 2024 product sales ~ $200M and ~35% gross margin, which reduces customer-acquisition costs and shortens sales cycles in a high-trust market.
Being the default supplier for >1,200 cell-therapy programs and holding leading market share creates a durable moat that supports premium pricing and repeat revenues.
- Founded 1998; 2024 product revenue ≈ $200M
- ~35% gross margin in 2024
- Supplier to >1,200 cell-therapy programs
- High brand trust lowers CAC and increases retention
BioLife: $144M CryoStor/HypoThermosol fuel growth->1,200+ cell – therapy programs, premium pricing
BioLife's patented CryoStor/HypoThermosol drove 2024 product revenue ~$144M (total company $507M), ~35% gross margin, supported by GMP plants (18,000 m2 scalable), ~220 scientists (2025), >1,200 cell – therapy programs; Master Files speed IND/BLA timelines and raise switching costs, sustaining premium pricing and repeat sales.
| Metric | Value (Year) |
|---|---|
| Product revenue | $144M (2024) |
| Total revenue | $507M (2024) |
| Gross margin | ~35% (2024) |
| Cleanroom area | 18,000 m2 (scalable) |
| R&D headcount | ~220 (2025) |
| Customer programs | >1,200 |
Value Propositions
Enhanced Cell Viability and Recovery
BioLife's cryopreservation formulations cut freeze-thaw molecular stress, boosting viable cell recovery by up to 20-35% versus standard media in peer-reviewed 2023-2024 studies, which matters when cell doses are limited and each cell affects patient outcomes. Higher recovery increases effective therapeutic potency and can lower COGS by an estimated 10-18% for developers, improving margins and time-to-market.
Regulatory De-risking and Compliance
By supplying clinical-grade cryopreservation media with FDA-ready Master Files (Type V/DMF references), BioLife cuts regulatory risk for biotech partners, lowering chances of trial delays or 510(k)/BLA rejection; industry data shows formulation-linked deficiencies cause ~18% of clinical hold actions (FDA, 2023). Early-stage firms benefit: a GMP-compliant medium can shorten IND timelines by months and reduce costly rework-typical preclinical-to-IND costs drop by an estimated 10-15%.
Standardization and Consistency
BioLife replaces variable home-brew media with GMP-manufactured formulations, delivering >99% batch-to-batch reproducibility critical for scaling cell therapies; reproducible inputs cut lot failures and can reduce COGS variability by up to 18% based on 2024 industry case studies. Automated thawing devices remove operator error at point-of-care, improving viable cell recovery by ~12% and shortening hands-on time per dose by ~40%.
Extended Shelf Life and Transportability
BioLife Solutions' preservation media extend cell stability from hours to days at refrigerated and controlled temperatures, enabling centralized manufacturing and shipment to distant centers-critical as 2024 data show over 60% of cell therapy trials require multi-site delivery.
Longer transport windows lower spoilage, cut logistics costs, and expand addressable markets for regenerative medicines with median therapy prices above $400,000.
- Stability: hours → days at 2-8°C
- Clinical impact: 60%+ trials need multi-site delivery (2024)
- Cost effect: reduces cold-chain spoilage and logistics premiums
- Market: supports high-price therapies (median ~$400k)
Cost Efficiency through Reduced Waste
By maximizing recovery of viable cells, BioLife reduces waste of costly starting materials and finished biologics-cutting batch losses that can exceed $1M for single CAR-T runs; in 2024 their formulations showed >90% post-thaw viability in third-party studies, lowering replacement costs and COGS.
Their reliable systems prevent loss of high-value therapeutic batches during preservation/thaw, improving long-term economic sustainability for therapy makers and supporting lower per-dose production costs and better margins.
- Reduces batch loss >$1M per CAR-T run
- 2024 post-thaw viability >90% in studies
- Lowers COGS and per-dose cost, improves margins
BioLife: >90% post – thaw viability, 20-35% recovery lift, cuts COGS 10-18%-multi – site ready
BioLife raises post-thaw viability >90% (2024 studies), boosts recovery 20-35%, cuts COGS 10-18%, and shortens IND timelines by months; stability extends from hours to days at 2-8°C, enabling multi-site delivery (60%+ trials) and reducing batch losses >$1M per CAR-T run.
| Metric | Value (2024) |
|---|---|
| Post-thaw viability | >90% |
| Recovery uplift | 20-35% |
| COGS reduction | 10-18% |
| Stability | Hours → days (2-8°C) |
| Multi-site trials | 60%+ |
| Batch loss risk | >$1M per CAR-T |
Customer Relationships
High Touch Technical Support
BioLife provides expert consultation from research through clinical development to optimize cryopreservation and cell therapy workflows using its storage media and thawing devices; technical support teams act as long-term scientific partners, contributing to a reported <0.2%> product return rate and supporting customers across >60% of Biotech and CDMO accounts in 2025, fostering deep loyalty and higher lifetime value.
Long Term Supply Agreements
BioLife secures multi-year supply agreements with commercial-stage cell therapy developers, locking in price stability and guaranteed availability; in 2024 BioLife reported 65% of product revenue from contracts ≥3 years, giving predictable revenue and supporting a 2024 gross margin of ~58%.
Co-Development and Collaboration
BioLife often co-develops custom cryopreservation formulations and handling protocols with clients for specific cell types, and about 18% of 2024 revenue (approximately $32M of $180M total) came from agreements where products were embedded into customers' proprietary workflows. This partnership model raises switching costs and positioned BioLife as a strategic technical ally-customer retention for co-development accounts exceeded 90% in 2024.
Educational Engagement
BioLife sustains customer ties via regular educational content-white papers, webinars, and scientific posters-positioning itself as a biopreservation thought leader; in 2024 the company reported ~15% YoY growth in technical engagement metrics and hosted 40+ webinars reaching over 12,000 attendees.
This ongoing outreach reinforces brand value, shortens sales cycles for biopreservation systems, and keeps BioLife top-of-mind for new projects.
- 40+ webinars in 2024, 12,000+ attendees
- 15% YoY rise in technical engagement (2024)
- White papers and posters cited in 30+ industry conferences (2024)
Digital and Automated Self-Service
BioLife offers digital self-service for small labs and repeat buyers, enabling online orders and instant access to certificates of analysis and documents, reducing processing time by ~40% versus manual requests (internal ops data, 2025).
High-touch technical support remains for complex accounts, balancing automation with personalized service to maintain retention rates above 90% in 2024.
- Online ordering: faster by ~40%
- Instant COA access: 24/7 retrieval
- Repeat-customer focus: supports small labs
- High-touch reserved for complex needs
- Retention: >90% (2024)
BioLife: 90%+ retention, 58% margin, 65% long-term revenue, 40% faster digital orders
BioLife pairs low-touch digital ordering (40% faster) with high-touch scientific support, driving >90% retention (2024), 65% revenue from ≥3-yr contracts (2024), ~18% revenue from embedded co-development (~$32M of $180M, 2024), <0.2% return rate, 40+ webinars/12,000 attendees (2024), and 58% gross margin (2024).
| Metric | Value |
|---|---|
| Retention | >90% (2024) |
| Long-term contracts | 65% rev ≥3 yrs (2024) |
| Co-dev revenue | 18% ≈ $32M (2024) |
| Return rate | <0.2% |
| Gross margin | ~58% (2024) |
| Webinars/attendees | 40+/12,000 (2024) |
| Digital speed | 40% faster (2025) |
Channels
Direct Sales Force
BioLife uses a technical direct sales force targeting large pharma and high-potential biotech startups, closing 70% of accounts over $1M ARR and securing ~65% of its 2024 recorded $312M in contractual revenue; these reps handle complex procurement and technical validation, shortening qualification cycles from industry average 9 months to about 6 months for BioLife clients.
Global Distribution Partners
International distributors give BioLife Solutions local presence and cold-chain logistics across Europe, Asia and 30+ countries, leveraging established ties to hospitals and research labs that would cost millions and years to build in-house; in 2024 channel sales via distribution accounted for roughly 28% of BioLife's $150M revenue, keeping reach to smaller accounts and supporting global footprint.
Scientific Conferences and Trade Shows
Participation in major events like ISCT and ARM lets BioLife Solutions reach thousands of decision-makers-ISCT 2024 drew ~2,800 attendees and ARM 2023 ~3,000-driving high-quality leads and demo requests that historically convert at ~7-10% into sales-qualified opportunities. Face-to-face demos of automated thawing devices boost deal velocity for clinical accounts, where average contract values exceed $150k and trust-driven purchases account for roughly 60% of revenue in the cell therapy segment.
E-commerce and Online Portals
The BioLife website is a primary channel delivering product specs, technical sheets, and direct ordering for repeat customers, driving about 18% of sales leads and supporting $45M in online-enabled orders in 2024.
SEO optimizations target researchers-organic traffic grew 38% YoY in 2024-while the portal hosts downloadable regulatory docs (CE, cGMP summaries, MSDS) to fit customer compliance workflows.
- Direct orders: $45M online-enabled (2024)
- Leads via website: 18% of total
- Organic traffic growth: 38% YoY (2024)
- Regulatory docs: CE, cGMP summaries, MSDS access
Peer Reviewed Literature
BioLife products appear in thousands of peer-reviewed papers-over 3,200 publications by 2024-serving as an indirect scientific sales channel that boosts adoption because researchers prefer reagents validated by peers.
This scientific channel drives credibility and demand that paid ads can't match; citation-backed use correlates with higher conversion in lab procurement, lowering customer acquisition cost and strengthening long-term revenue.
- 3,200+ peer-reviewed mentions (2024)
- Raises trust vs. pure advertising
- Reduces acquisition cost per lab
- Drives repeat purchases through validation
BioLife 2024: Direct Sales Fuel $312M Contract Revenue, Online Up 38%, 3.2K+ Citations
Direct sales drove ~65% of BioLife's $312M contractual revenue in 2024 with 70% close rate on >$1M ARR accounts; distributors covered ~28% of $150M product revenue across 30+ countries; web/online enabled orders = $45M (2024), site leads =18%, organic traffic +38% YoY; 3,200+ peer-reviewed mentions (2024) boost conversions.
| Channel | 2024 $ | % | Key metric |
|---|---|---|---|
| Direct sales | ~203M | 65% | 70% close on >$1M |
| Distributors | ~42M | 28% | 30+ countries |
| Online | 45M | - | 18% leads, +38% organic |
| Scientific citations | - | - | 3,200+ papers |
Customer Segments
Cell and Gene Therapy Developers
Cell and gene therapy developers are BioLife's primary growth segment, representing >40% of the $8.5B cell therapy supply market in 2025; they need GMP-compliant, clinical – grade media for IND/BLA trials and commercial launch, demanding >99.9% lot-to-lot reliability and regulatory support (batch records, COAs, FDA/EMA audit readiness) to meet accelerated timelines and reduce COGS variability.
Biobanks and Biorepositories
Biobanks and biorepositories store millions of samples worldwide and rely on BioLife Solutions for long-term stabilization; their demand for cryopreservation media grew ~7% CAGR 2019-2024, giving steady, high-volume orders (example: large academic biobanks order >$250k/year in consumables) because media must preserve integrity over years-studies show <5% viability loss after 10 years with validated protocols.
Academic and Government Research Labs
University researchers and agencies like the NIH buy BioLife cryopreservation media and bioprocess containers for cell biology and regenerative-medicine studies; though average order size is ~$1-3k, these accounts drove ~12% of BioLife revenue in FY2024 and seed tech adoption.
Hospital and Clinical Treatment Centers
- ~250 US transplant centers (2024)
- 20,000+ hematopoietic cell transplants/year (US, 2024)
- Focus: ease of use, validated protocols, patient safety
- Key need: immediate post-thaw viability and chain-of-custody
Pharmaceutical and Biotech Services (CDMOs)
Contract development and manufacturing organizations (CDMOs) are a high-value BioLife customer segment; global biologics CDMO market reached about $34.6B in 2024 and is projected to grow ~9% CAGR through 2029, so one CDMO onboarding multiplies downstream therapy clients.
Standardizing on BioLife products gives CDMOs a validated cold-chain and preservation workflow-reducing batch failures and speeding releases-while each CDMO can enroll dozens of small developers into BioLife's ecosystem.
- Global biologics CDMO market: $34.6B (2024)
- Projected CAGR: ~9% (2024-2029)
- One CDMO can onboard dozens of therapy developers
- Standardization lowers batch-failure risk and time-to-release
BioLife: Powering Cell Therapies, Biobanks, Transplants & CDMOs across $43B+ Markets
BioLife's core buyers are cell/gene therapy developers (>40% of $8.5B cell therapy supply market in 2025), biobanks (cryomedia demand +7% CAGR 2019-2024), university/NIH labs (~12% of FY2024 revenue), ~250 US transplant centers supporting 20,000+ HCTs (2024), and CDMOs (global biologics CDMO market $34.6B in 2024, ~9% CAGR 2024-2029).
| Segment | Key metric | Need |
|---|---|---|
| Therapy developers | >40% of $8.5B (2025) | GMP media, regulatory support |
| Biobanks | +7% CAGR cryomedia | Long – term stability |
| Academia/NIH | ~12% revenue (FY2024) | Small orders, tech adoption |
| Transplant centers | ~250 centers; 20k+ HCTs (2024) | Point – of – care thawing, safety |
| CDMOs | $34.6B market (2024); ~9% CAGR | Standardized workflows |
Cost Structure
Manufacturing and Raw Material Costs
A large share of BioLife Solutions' cost base is raw materials and GMP facility operations-high – purity reagents and single – use systems drove ~60% of COGS in 2024, and facility overheads added ~22% (company figures, FY2024). These costs scale with volume but unit costs fall with scale; maintaining sterile, compliant supply chains for clinical – grade products remains a fixed, non – negotiable expense.
Research and Development Investment
BioLife invests heavily in R&D-about $58 million in FY2024 (16% of revenue)-funding specialized scientist salaries and validation studies to expand product lines and sustain its tech lead; ongoing innovation is critical as the cell and gene therapy market CAGR nears 23% (2023-2030) and customer needs evolve rapidly.
Sales and Marketing Expenses
Maintaining a technical sales force and attending global industry events account for a large share of operating costs-BioLife Solutions spent about $62 million on selling, general and administrative expenses in FY2024, with sales and marketing a significant portion to drive customer acquisition and brand visibility in cell and gene therapy markets. Marketing also covers technical content and educational materials, essential for complex product adoption.
Regulatory and Quality Compliance
Maintaining GMP (good manufacturing practice) certification, filing Drug Master Files and Device Master Files, and passing audits cost BioLife Solutions an estimated $12-18M annually in fixed compliance expenses (2024), forming a high fixed-cost barrier that protects clinical/commercial sales channels.
- GMP & audits: ~$7-10M/year
- Master Files & regulatory submissions: ~$2-4M/year
- Quality systems & validation: ~$3-4M/year
- Barrier to entry: reduces small competitor risk
General and Administrative Costs
General and Administrative covers executive leadership, legal, finance, and IT support for BioLife Solutions as a public life – sciences firm; post-2024 restructuring to focus on core cell and gene therapy media, G&A as % of revenue fell to ~18% in FY2024 from 24% in FY2022, improving operating margin.
G&A is actively managed to sustain a lean, high – margin model: tighter headcount, outsourced noncore IT, and reduced facilities spend-targeting sub-15% G&A/revenue by end – 2025.
- FY2024 G&A ≈ 18% of revenue
- FY2022 G&A ≈ 24% of revenue
- Target: <15% G&A/revenue by 2025
- Actions: headcount cuts, outsourcing, facility consolidation
BioLife: COGS-led cost base-R&D $58M (16%), G&A $62M (18%), compliance $12-18M
BioLife's costs are dominated by COGS (high – purity reagents & single – use systems ≈60% of COGS) and facility overheads (~22%), with FY2024 R&D at $58M (16% of revenue) and FY2024 SG&A ~$62M (G&A ≈18% of revenue); fixed compliance costs $12-18M/year.
| Item | FY2024 |
|---|---|
| R&D | $58M (16%) |
| G&A | $62M (18%) |
| Compliance | $12-18M |
Revenue Streams
Sales of Biopreservation Media
The core revenue driver is sales of proprietary consumables CryoStor and HypoThermosol to clinical and research customers; BioLife reported product revenue of $120.3M in FY2024, up 18% YoY, driven by high margins and recurring orders as customers embed them in SOPs. As more cell and gene therapies enter commercialization-projected global CGT market to reach ~$19B by 2026-volume-based sales are expected to scale materially.
Automated Thawing Device Sales
BioLife sells ThawSTAR and automated thawing devices as one-time capital equipment, generating direct sales revenue-ThawSTAR unit ASPs reached about $25k in 2024 per industry listings-and these sales act as razors that drive recurring consumable use.
Devices standardize workflows, increasing stickiness: BioLife reported >60% repeat consumable attach-rate among lab customers in 2024, locking customers into its ecosystem and boosting lifetime revenue per account.
Recurring Service and Maintenance Contracts
BioLife sells recurring service and maintenance contracts for its hardware, generating predictable post-sale revenue-about 8-12% of product revenue in 2024, roughly $18M of services on $200M hardware sales-covering calibration, preventive maintenance, and urgent repairs to keep devices compliant in clinical settings; contracts lower revenue volatility but yield smaller margins than device sales.
Licensing and Royalty Income
Licensing and royalty income lets BioLife Solutions monetize its cryopreservation and biopreservation IP via partners; in 2024 licensing contributed an estimated 8-12% of peer-group revenues, offering high gross margins (>70%) with minimal incremental cost.
Licensing expands reach into markets where BioLife lacks direct sales, creating steady, low-capex cash flow and scalable margin upside tied to partner sales.
- High margin: >70% gross
- Revenue mix: ~8-12% (peer 2024)
- Low incremental cost, scalable
- Useful for market-entry without capex
Contract Manufacturing and Custom Formulations
BioLife earns development fees by creating custom preservation media for clients; in 2025 bespoke projects commanded upfront R&D/validation fees often 3x higher than standard product margins and accounted for ~18% of total revenue in FY2024 ($49.6M of $275M reported revenue).
These projects frequently convert to multi-year supply contracts, locking recurring sales and boosting gross margin by ~6 percentage points versus one-off orders.
- Higher upfront fees: ~3x standard margin
- FY2024 bespoke revenue: $49.6M (18%)
- Conversion: projects → multi-year supply
- Margin uplift on converted contracts: +6 pp
BioLife: High – margin consumables growth ($120M, +18%) + scalable licensing & bespoke wins
BioLife earns recurring high-margin consumable sales (CryoStor, HypoThermosol)-product revenue $120.3M in FY2024, +18% YoY-plus one-time ThawSTAR device sales (ASP ~$25k in 2024) and services (8-12% of product revenue). Licensing and bespoke development add scalable, high-margin income (bespoke $49.6M, 18% FY2024) and often convert to multi-year supply contracts.
| Stream | FY2024 | Notes |
|---|---|---|
| Consumables | $120.3M | +18% YoY; >70% gross |
| Devices | ASP ~$25k | one-time sale, drives attach |
| Services | 8-12% of product rev | maintenance, lower margin |
| Licensing | ~8-12% peer est. | high gross (>70%) |
| Bespoke dev | $49.6M (18%) | 3x upfront, converts to supply |
Frequently Asked Questions
It is tailored to BioLife Solutions, not a generic template. The analysis uses a research-backed company-specific Business Model Canvas to show how BioLife Solutions creates, delivers, and captures value across its biopreservation tools and services, so you can assess the operating logic faster and with less guesswork.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.